- Home
- UBS vs GILD Comparison
UBS vs GILD Comparison
Compare UBS & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBS
- GILD
- Stock Information
- Founded
- UBS 1862
- GILD 1987
- Country
- UBS Switzerland
- GILD United States
- Employees
- UBS N/A
- GILD N/A
- Industry
- UBS Major Banks
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UBS Finance
- GILD Health Care
- Exchange
- UBS Nasdaq
- GILD Nasdaq
- Market Cap
- UBS 122.4B
- GILD 145.4B
- IPO Year
- UBS N/A
- GILD 1992
- Fundamental
- Price
- UBS $38.21
- GILD $118.81
- Analyst Decision
- UBS Buy
- GILD Buy
- Analyst Count
- UBS 3
- GILD 22
- Target Price
- UBS N/A
- GILD $118.76
- AVG Volume (30 Days)
- UBS 1.9M
- GILD 6.9M
- Earning Date
- UBS 10-29-2025
- GILD 10-30-2025
- Dividend Yield
- UBS 1.94%
- GILD 2.67%
- EPS Growth
- UBS 84.33
- GILD 496.80
- EPS
- UBS 2.21
- GILD 5.01
- Revenue
- UBS $48,193,000,000.00
- GILD $28,863,000,000.00
- Revenue This Year
- UBS $3.51
- GILD $2.25
- Revenue Next Year
- UBS $3.55
- GILD $3.77
- P/E Ratio
- UBS $16.60
- GILD $23.65
- Revenue Growth
- UBS 2.09
- GILD 3.81
- 52 Week Low
- UBS $25.75
- GILD $86.08
- 52 Week High
- UBS $42.57
- GILD $124.61
- Technical
- Relative Strength Index (RSI)
- UBS 39.99
- GILD 52.93
- Support Level
- UBS $38.12
- GILD $116.81
- Resistance Level
- UBS $39.21
- GILD $121.58
- Average True Range (ATR)
- UBS 0.41
- GILD 2.62
- MACD
- UBS -0.05
- GILD -0.30
- Stochastic Oscillator
- UBS 21.76
- GILD 34.17
About UBS UBS Group AG Registered
The core of UBS is its global wealth management business focusing on high and ultra-high-net-worth individuals. UBS is also a conventional retail and commercial bank in its Swiss home market. Its investment bank and asset management businesses support its wealth management operations, but also leverage its strength in wealth management to serve third-party clients.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).